Advertisement

Topics

Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer

08:01 EDT 16 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Expect to Open Expansion Cohorts in Phase 1 Trial in Mid-2018, Including Cohorts Evaluating SY-1365 as a Single and Combination Agent in Multiple Ovarian Cancer Patient Populations On Track to Report Data from Dose Esca...

Other Sources for this Article

Media Contact:
Syros Pharmaceuticals
Naomi Aoki, 617-283-4298
naoki@syros.com
or
Investor Contact:
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
hannahd@sternir.com

NEXT ARTICLE

More From BioPortfolio on "Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...